LYMPHOMA, NON-HODGKIN

This study tests whether extra COVID-19 vaccine doses can improve protection for people with weakened immune systems, including those with HIV, organ transplants, or blood cancers. About 960 participants will receive different booster schedules to see which works best. The goal i…

This early-phase study tests NKX019, a therapy made from donor immune cells (natural killer cells) that are engineered to find and attack cancer cells. It is for adults with certain blood cancers (like lymphoma or leukemia) that have come back or not responded to other treatments…

This early-stage study is testing an experimental drug called JNJ-88998377 in 58 people with B-cell non-Hodgkin's lymphoma that has returned or not responded to prior treatments. The main goals are to check the drug's safety and find the best dose for future studies. Participants…

This study tests whether siltuximab can lessen the severity of cytokine release syndrome (CRS) and nerve-related side effects (ICANS) in 30 people receiving CAR-T cell therapy for blood cancers like lymphoma and multiple myeloma. The goal is to help patients recover faster from t…

This early-stage study tests a new drug (JNJ-87801493) combined with immune-boosting T-cell engagers in about 70 people whose B-cell non-Hodgkin lymphoma has returned or not responded to other treatments. The main goals are to check safety and find the best dose. This is not a cu…

This study tested a stem cell transplant using blood stem cells from a half-matched (haploidentical) donor in 21 people with various blood cancers like leukemia and lymphoma. The goal was to see if this approach could help patients survive and recover without severe side effects.…

This early-phase study tests a new cell therapy for patients with relapsed EBV-positive lymphoma. The treatment uses the patient's own immune cells, modified to resist a tumor's defense mechanism (TGFb) and trained to attack cancer cells. The main goals are to find a safe dose an…

This early-stage study tests a new drug, JNJ-80948543, designed to help the body's immune cells attack cancer. It is for adults with certain blood cancers (non-Hodgkin lymphoma or chronic lymphocytic leukemia) that have not responded to other treatments. The main goals are to che…

This study tests a treatment called JCAR017, made from a patient's own immune cells that are modified to attack cancer. It is for adults with a slow-growing type of non-Hodgkin lymphoma that has come back or not responded to prior therapy. The goal is to see if the treatment can …

This study tests a new treatment for people with Hodgkin or non-Hodgkin lymphoma that has come back or not responded to other therapies. The treatment uses the patient's own immune cells (T cells) that are modified in a lab to recognize and attack cancer cells carrying a protein …

This study tests a two-step transplant approach for people with high-risk non-Hodgkin's lymphoma. First, patients receive their own stem cells, followed by a donor transplant to boost long-term disease control. The goal is to improve survival and manage the cancer, not to cure it…

This study looks at the long-term safety of the drug pirtobrutinib in people with certain blood cancers, like chronic lymphocytic leukemia or non-Hodgkin lymphoma. Participants must have already completed an earlier study and still benefit from the drug. They receive treatment ev…

This early-phase study tests a new drug combination (JNJ-80948543 plus another T-cell engager) in 19 adults with relapsed or refractory B-cell non-Hodgkin lymphoma, a type of blood cancer that has not responded to at least two prior treatments. The main goals are to find the safe…

This study tests an experimental oral drug called CC-99282, taken alone or with other lymphoma treatments, in people whose non-Hodgkin lymphoma has returned or not responded to prior therapy. The main goals are to check safety, find the best dose, and see if the drug helps shrink…

This study tests a new drug, englumafusp alfa, combined with two other drugs (obinutuzumab and glofitamab) in people whose B-cell Non-Hodgkin's lymphoma has returned or stopped responding to treatment. The goal is to see if the combination is safe and can shrink tumors. About 498…

This study offers ongoing access to ibrutinib for 297 people with certain blood cancers or graft-versus-host disease who completed earlier ibrutinib trials and still benefit from the drug but cannot get it commercially. Participants continue their current treatment while research…

This early-stage study tests an experimental pill called LOXO-338 in people with advanced blood cancers (like certain leukemias, lymphomas, and multiple myeloma) who have already tried standard treatments. The main goals are to find the safest dose and to see if the drug can shri…

This study tests a program that combines mindfulness and music therapy, delivered through an app or website, to help people who are getting a stem cell transplant feel better and have a higher quality of life. About 60 adults with certain blood cancers will try the program during…

This study tests a new way to calculate the dose of melphalan chemotherapy for lymphoma patients getting a stem cell transplant. Instead of a standard dose based on height and weight, researchers use a model that considers how previous patients processed the drug, aiming for the …

This study tracks about 50 people who previously received an experimental CAR T cell therapy for several types of lymphoma. The goal is to watch for long-term side effects and check how well patients do over 15 years. No new treatment is given, but patients can receive other canc…

This study enrolls 120 people with different cancers who already received treatment in an earlier study. The goal is to track serious side effects and other health issues over time. No new treatment is given; participants are simply monitored for safety.

This study tracks 150 people who previously received Caribou cell therapy for blood cancers like lymphoma or leukemia. The goal is to watch for long-term side effects and safety issues over 15 years. No new treatment is given—just regular check-ups to see how patients are doing.…

This study collects blood or saliva samples from people with cancer and their relatives to build a DNA bank. Researchers will use these samples to study how genes may increase the risk of developing certain cancers. About 992 participants are expected. No treatment or direct bene…

This study is building a large group of 21,000 people newly diagnosed with non-Hodgkin lymphoma to track their health over time. Researchers will look at medical history, lifestyle, genetics, and treatments to find out what affects survival, side effects, and quality of life. The…